ProQR Therapeutics (PRQR) Non Operating Income (2013 - 2026)
ProQR Therapeutics (PRQR) posted Non Operating Income of $248198.1 for Q1 2026, down 24.18% sequentially from $327335.4 in Q3 2025, and up 146.45% YoY from $100710.1 in Q1 2025.
ProQR Therapeutics (PRQR) Non Operating Income (2013 - 2026) Analysis & Trends
ProQR Therapeutics has reported Non Operating Income for 14 years, with the latest figure at $248198.1 in Q1 2026.
- Quarterly Non Operating Income rose 146.45% year-over-year to $248198.1 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $258512.5 (up 8498.64% YoY) and the FY2021 annual result came in at $3.3 million, up 177.79% from the prior year.
- Non Operating Income declined to $248198.1 in Q1 2026 per PRQR's latest filing, from $327335.4 in the prior quarter.
- Over five years, Non Operating Income peaked at $1.4 million in Q1 2022 and troughed at -$583897.9 in Q1 2023.
- A 5-year average of $336684.4 and a median of $395158.3 in 2023 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2022 and 2023: Non Operating Income jumped 499.81% in 2022, then slumped 141.32% in 2023.
- Over 5 years, Non Operating Income stood at $603956.3 in 2022, then sank by 34.57% to $395158.3 in 2023, then jumped by 30.34% to $515064.9 in 2024, then slumped by 36.45% to $327335.4 in 2025, then dropped by 24.18% to $248198.1 in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $248198.1, $327335.4, and $217336.3 for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | ProQR Therapeutics | 206.80 Mn | 111.86 Mn | - | 248,198.08 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 248,198.08 |
| Sep 30, 2025 | 327,335.43 |
| Jun 30, 2025 | 217,336.26 |
| Mar 31, 2025 | -534,357.30 |
| Sep 30, 2024 | 515,064.95 |
| Jun 30, 2024 | 552,443.33 |
| Mar 31, 2024 | -530,144.54 |
| Sep 30, 2023 | 395,158.34 |
| Jun 30, 2023 | 511,794.46 |
| Mar 31, 2023 | -583,897.95 |
| Sep 30, 2022 | 603,956.32 |
| Jun 30, 2022 | 1.24 Mn |
| Mar 31, 2022 | 1.41 Mn |
| Dec 31, 2021 | 340,903.34 |
| Sep 30, 2021 | 313,690.43 |
| Jun 30, 2021 | -2.97 Mn |
| Mar 31, 2021 | -353,427.18 |
| Dec 31, 2020 | 2.02 Mn |
| Sep 30, 2020 | -2.18 Mn |
| Jun 30, 2020 | -767,717.71 |